Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Faecal elastase is an enzyme test used to identify the presence of pancreatic exocrine
insufficiency. This condition manifests with symptoms of diarrhea, weight loss, causing
potential impairment on an individual's quality of life. Creon, a pancreatic enzyme
supplement, marketed by Abbott Laboratories, Inc. is currently the standard treatment for
this condition. However, there has been limited work evaluating the merits of this medication
in this condition. This study aims to evaluate the benefits that Creon may have in coeliac
patients with low faecal pancreatic elastase by randomising patients with low faecal
pancreatic elastase (<200 ug/g) to either treatment with Creon or placebo. Outcome measures
that we aim to assess to determine the benefits of Creon include evaluation of stool
frequency, abdominal pain, body mass index (BMI) and quality of life.